Patents by Inventor Poul Nielsen
Poul Nielsen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230219964Abstract: Compounds of formula (1) comprising a pleuromutilin backbone with a triazole based side-group at C22 are provided. The compounds can be used for treatment of bacterial infections and fungal infections. Importantly, infections caused by multidrug-resistant bacteria, such as methicillin-resistant Staphylococcus aureus (MRSA) may be treated effectively.Type: ApplicationFiled: April 29, 2021Publication date: July 13, 2023Inventors: Poul NIELSEN, Christoffer Vogsen HEIDTMANN
-
Patent number: 8153365Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: GrantFiled: June 3, 2010Date of Patent: April 10, 2012Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 8080644Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: GrantFiled: August 13, 2008Date of Patent: December 20, 2011Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 8034909Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: GrantFiled: August 15, 2008Date of Patent: October 11, 2011Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20110245327Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: ApplicationFiled: June 3, 2010Publication date: October 6, 2011Applicant: Exiqon A/SInventors: Jesper WENGEL, Poul Nielsen
-
Publication number: 20100279895Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: ApplicationFiled: August 15, 2008Publication date: November 4, 2010Applicant: EXIQON A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20100267018Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: ApplicationFiled: August 13, 2008Publication date: October 21, 2010Applicant: EXIQON A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 7572582Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: GrantFiled: May 18, 2005Date of Patent: August 11, 2009Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20060235090Abstract: The invention provides a process for production of methanol from a feed stream rich in hydrogen carbon monoxide and carbon dioxide. The feed stream is converted to a converted process stream comprising methanol and small amounts of higher alcohols, aldehydes and ketones in the presence of a catalyst active in conversion of hydrogen and carbon monoxide into methanol. The converted process stream is cooled to a cooled process stream to 20-200° C. The cooled process stream is hydrogenated into a hydrogenated process stream rich in methanol and depleted in aldehydes and ketones in presence of a hydrogenation catalyst. The catalyst is active in conversion of aldehydes and ketones into alcohols in a process stream rich in methanol and further comprising hydrogen, carbon monoxide and carbon dioxide. The hydrogenated process stream is cooled to a cooled, condensed process stream, and subsequently the cooled, condensed process stream is separated into a gas phase and a liquid crude methanol phase.Type: ApplicationFiled: December 9, 2003Publication date: October 19, 2006Applicant: HALDOR TOPSOE A/SInventors: Poul Nielsen, Susanne Jorgensen
-
Publication number: 20060168888Abstract: A process for the preparation of a hydrogen-rich stream comprising contacting a process gas containing carbon monoxide and water, the process gas further including dimethyl ether or a dimethyl ether/methanol mixture in at least one shift step in the presence of an ether hydration catalyst selected from the group of solid acids and a methanol decomposition catalyst comprising copper, zinc and aluminium and/or chromium.Type: ApplicationFiled: March 25, 2004Publication date: August 3, 2006Inventors: Poul Nielsen, John Hansen, Niels Schiodt
-
Publication number: 20060165589Abstract: A process for the preparation of a hydrogen-rich stream comprising contacting a carbon monoxide-containing gas, methanol and water in at least one shift step in the presence of a catalyst comprising copper, zinc and aluminium and/or chromium at a shift inlet temperature of at least 280° C. and a pressure of at least 2.0 MPa.Type: ApplicationFiled: March 25, 2004Publication date: July 27, 2006Inventors: Poul Nielsen, John Hansen, Niels Schiodt
-
Patent number: 7034133Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: GrantFiled: July 29, 2002Date of Patent: April 25, 2006Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20060015121Abstract: The invention concerns a measuring instrument, preferably for use in connection with press fit hip prosthesis surgery, whereby it is possible to measure/register size (diameter) and modulus of elasticity of acetabulum and femur for inserting an uncemented socket or uncemented femur component.Type: ApplicationFiled: October 21, 2003Publication date: January 19, 2006Inventor: Poul Nielsen
-
Publication number: 20050287566Abstract: The present invention relates to novel bicyclic and tricyclic nucleoside and nucleotide analogues as well as to oligonucleotides comprising such elements. The nucleotide analogues, LNAs (Locked Nucleoside Analogues), are able to provide valuable improvements to oligonucleotides with respect to affinity and specificity towards complementary RNA and DNA oligomers. The novel type of LNA modified oligonucleotides, as well as the LNAs as such, are useful in a wide range of diagnostic applications as well as therapeutic applications. Among these can be mentioned antisense applications, PCR applications, strand displacement oligomers, as substrates for nucleic acid polymerases, as nucleotide based drugs, etc. The present invention also relates to such applications.Type: ApplicationFiled: May 18, 2005Publication date: December 29, 2005Inventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20050256175Abstract: Novel compounds that act to antagonize the action of the glucagon peptide hormone on the glucagon receptor. More particularly, it relates to glucagon antagonists or inverse agonists.Type: ApplicationFiled: February 22, 2005Publication date: November 17, 2005Inventors: Jesper Lau, Inger Christensen, Peter Madsen, Paw Bloch, Carsten Behrens, Janos Kodra, Poul Nielsen
-
Publication number: 20050108941Abstract: Process for production of synthesis gas comprising carbon monoxide, carbon dioxide and hydrogen by reforming of methanol including the steps of: (a) introducing methanol in liquid phase into a reactor containing a solid methanol reforming catalyst suspended in a liquid phase of methanol and water; (b) reacting the liquid phase of methanol and water in presence of the suspended catalyst at a pressure and temperature, where methanol is maintained in the liquid phase; and (c) withdrawing from the reactor a gas phase of synthesis gas being produced during reaction of the liquid methanol and water phase.Type: ApplicationFiled: November 17, 2004Publication date: May 26, 2005Inventors: Poul Nielsen, Jens Perregaard
-
Patent number: 6794499Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes will single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: GrantFiled: September 11, 1998Date of Patent: September 21, 2004Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Patent number: 6670461Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: GrantFiled: May 9, 2001Date of Patent: December 30, 2003Assignee: Exiqon A/SInventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20030144231Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri, or polycyclic nucleoside analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: ApplicationFiled: July 29, 2002Publication date: July 31, 2003Inventors: Jesper Wengel, Poul Nielsen
-
Publication number: 20020068708Abstract: Novel oligomers, and synthesis thereof, comprising one or more bi-, tri-, or polycyclic nucleotide analogues are disclosed herein. The nucleoside analogues have a “locked” structure, termed Locked Nucleoside Analogues (LNA). LNA's exhibit highly desirable and useful properties. LNA's are capable of forming nucleobase specific duplexes and triplexes with single and double stranded nucleic acids. These complexes exhibit higher thermostability than the corresponding complexes formed with normal nucleic acids. The properties of LNA's allow for a wide range of uses such as diagnostic agents and therapeutic agents in a mammal suffering from or susceptible to, various diseases.Type: ApplicationFiled: September 11, 1998Publication date: June 6, 2002Inventors: JESPER WENGEL, POUL NIELSEN